Health Condition 1: M059- Rheumatoid arthritis with rheumatoid factor, unspecified
Conditions
Interventions
None listed
Sponsors
Dr. Aishwarya Gadhar
Eligibility
Inclusion criteria
Inclusion criteria: 1.Subjects of age group between 20 to 60 yrs, of both genders with chronicity equal to or less than five-year duration will be selected 2.Subjects of Amavata diagnosed on the basis of signs & symptoms described in Ayurvedic classics will be selected for the study. 3.Subjects diagnosed as Amavata with features of Rheumatoid arthritis as specified in European League Against Rheumatism/ American College of Rheumatology 2010 criteria i.e., 2010 ACR-EULAR diagnostic criteria will be selected for the study. 4.Subjects fit for Sthanika valuka sweda, wax therapy and Kshara basti will be selected for the study. 5.Subjects who are in Stage 1 or Stage 2 of the disease based on its severity and physical limitations. 6.Subjects voluntarily willing to give written consent and participate in the study. 7.Subjects currently on NSAIDs and DMARDs, or any other medication which may affect the course of treatment shall be included after a washout period.
Exclusion criteria
Exclusion criteria: 1.Subjects of both genders with chronicity of disease more than 5 years with any joint deformity. 2.Subjects with any systemic disease or condition that would potentially interfere with the course of treatment. 3.Subjects contraindicated for Sthanika Valuka Sweda, Wax therapy and Kshara Basti. 4.Subjects with the signs and symptoms of Pravruddha Amavata with joint deformities in STAGE-3 & STAGE-4. 5.Pregnant and lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.Significant reduction in signs and symptoms of Amavata vis-a-vis Rheumatoid Arthritis based on subjective like Sandhishoola, Sandhistabdhata and Sandhishopha and objective parameters like DAS 28 SCORE and Barthel s Index Score for assessing Quality of Life . 2.Establishment of clinical efficacy of Wax Therapy and Sthanika Valuka Sweda with Kshara basti in management of Amavata vis-a-vis Rheumatoid Arthritis. Timepoint: 0th day : Before commencement of treatment. 8th day : After completion of the treatment. 24th day: After Basti Parihara Kala. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.Generation of data on possible unexpected / adverse drug reactions or events 2.Generation of data on quality of life with the test treatment modalities 3.Generation of in-depth analysed data on different aspects of the disease Timepoint: 1.0th day : Before commencement of treatment. 2.8th day : After completion of the treatment. 3.24th day: After Basti Parihara Kala. | — |
Countries
India
Contacts
Public ContactDr Prajwal Narayan
Sri Sri College of Ayurvedic Science and Research Hospital
Outcome results
None listed